[go: up one dir, main page]

WO2005051353A3 - Pharmaceutical formulations comprising voriconazole - Google Patents

Pharmaceutical formulations comprising voriconazole Download PDF

Info

Publication number
WO2005051353A3
WO2005051353A3 PCT/IB2004/003746 IB2004003746W WO2005051353A3 WO 2005051353 A3 WO2005051353 A3 WO 2005051353A3 IB 2004003746 W IB2004003746 W IB 2004003746W WO 2005051353 A3 WO2005051353 A3 WO 2005051353A3
Authority
WO
WIPO (PCT)
Prior art keywords
voriconazole
pharmaceutical formulations
formulation
poloxamers
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/003746
Other languages
French (fr)
Other versions
WO2005051353A2 (en
WO2005051353A8 (en
Inventor
Michael John Humphrey
Tobin Andrew Payne-Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Ltd Great Britain
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Ltd Great Britain
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Ltd Great Britain, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of WO2005051353A2 publication Critical patent/WO2005051353A2/en
Publication of WO2005051353A3 publication Critical patent/WO2005051353A3/en
Publication of WO2005051353A8 publication Critical patent/WO2005051353A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

This invention relates to a new pharmaceutical formulation of voriconazole, in particular a formulation comprising one or more poloxamers.
PCT/IB2004/003746 2003-11-25 2004-11-12 Pharmaceutical formulations comprising voriconazole Ceased WO2005051353A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0327390A GB0327390D0 (en) 2003-11-25 2003-11-25 Pharmaceutical formulations
GB0327390.1 2003-11-25

Publications (3)

Publication Number Publication Date
WO2005051353A2 WO2005051353A2 (en) 2005-06-09
WO2005051353A3 true WO2005051353A3 (en) 2005-10-27
WO2005051353A8 WO2005051353A8 (en) 2006-05-18

Family

ID=29797775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003746 Ceased WO2005051353A2 (en) 2003-11-25 2004-11-12 Pharmaceutical formulations comprising voriconazole

Country Status (2)

Country Link
GB (1) GB0327390D0 (en)
WO (1) WO2005051353A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2027850A1 (en) * 2007-08-22 2009-02-25 Sandoz AG Pharmaceutical compositions containing voriconazole
CN101444510B (en) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 Pharmaceutical preparation containing voriconazole and preparation method thereof
WO2013167865A1 (en) * 2012-05-11 2013-11-14 Cipla Limited Pharmaceutical composition
CN104188904B (en) * 2014-09-28 2017-02-22 湖北工业大学 Eye use voriconazole nanocrystal preparation and preparation method thereof
CN113662914A (en) * 2021-08-25 2021-11-19 兆科药业（合肥）有限公司 Ophthalmic gel containing voriconazole and preparation method and application thereof
PL247580B1 (en) * 2023-02-09 2025-07-28 Univ Medyczny Im Piastow Slaskich We Wroclawiu Pharmaceutical composition with fluconazole with increased antifungal activity, form of the pharmaceutical composition and use of the pharmaceutical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058677A1 (en) * 1997-06-21 1998-12-30 Pfizer Limited Pharmaceutical formulations containing voriconazole
WO2001064187A2 (en) * 2000-02-29 2001-09-07 Maelor Pharmaceuticals Limited Anaesthetic formulations
WO2002055059A2 (en) * 2000-12-22 2002-07-18 Baxter Int Method for preparing submicron particle suspensions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058677A1 (en) * 1997-06-21 1998-12-30 Pfizer Limited Pharmaceutical formulations containing voriconazole
WO2001064187A2 (en) * 2000-02-29 2001-09-07 Maelor Pharmaceuticals Limited Anaesthetic formulations
WO2002055059A2 (en) * 2000-12-22 2002-07-18 Baxter Int Method for preparing submicron particle suspensions

Also Published As

Publication number Publication date
WO2005051353A2 (en) 2005-06-09
GB0327390D0 (en) 2003-12-31
WO2005051353A8 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
MXPA03007215A (en) Pharmaceutical formulations.
AP2405A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms.
IL173571A0 (en) Injectable, oral, or topical sustained release pharmaceutical formulations
EP1631239A4 (en) Pharmaceutical compositions comprising active vitamin d compounds
MXPA03006775A (en) Pharmaceutical formulation.
DK1615646T4 (en) PHARMACEUTICAL FORMULATIONS CONTAINING METHYLNALTREXONE
NO20052306D0 (en) Dispersible pharmaceutical compositions.
GB0302671D0 (en) Pharmaceutical formulations
MXPA03007641A (en) Pharmaceutical formulation.
WO2006074398A3 (en) Sustained release pharmaceutical formulations comprising ranolazine
IL172824A0 (en) Pharmaceutical formulations
WO2010046061A3 (en) Cosmetic and/or pharmaceutical formulations
EP1620112A4 (en) DESMOGLEINE 4, THE NEW GENE OF HAIR GROWTH
GB0302672D0 (en) Pharmaceutical formulations
WO2005030142A8 (en) Rifalazil formulations
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2005051353A3 (en) Pharmaceutical formulations comprising voriconazole
WO2005060981A3 (en) Pharmaceutical compositions
GB0316341D0 (en) Pharmaceutical formulations
HU0304095D0 (en) Novel, effective pharmaceutical compositions
ITTO20030850A1 (en) PROCEDURE FOR THE PREPARATION OF 4-AMINO-3,5-DICLORO-BENZOTRIFLORURO.
IL172304A0 (en) Pharmaceutical compositions comprising active vitamin d compounds
ZA200204905B (en) Improved pharmaceutical dental formulations.
AU2003283508A1 (en) .pharmaceutical composition comprising htless thansbgreater than4less than/sbgreater thandless thanspgreater than100less than/spgreater thana receptors, and therapeutic uses thereof
GB0316335D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase